RE: In danger of going blue10 Jun 2025 14:08
Johnson & Johnson (J&J) stands out as the best fit among the big US pharma companies:
J&J has made a major strategic bet on mental health, recently acquiring Intra-Cellular Therapies for $14.6 billion to access CAPLYTA, a novel CNS drug for depression and schizophrenia.
This acquisition signals J&J’s commitment to expanding its mental health pipeline and willingness to invest heavily in innovative CNS assets.
J&J’s broad commercial reach in psychiatry, strong R&D capabilities, and history of successfully developing and marketing CNS drugs make it well-positioned to advance Solvonis’s novel PTSD and addiction therapies.